Bet_Noire
The FDA has approved UCB’s (OTCPK:UCBJF) (OTCPK:UCBJF) Bimzelx, also known as bimekizumab, for the treatment of moderate-to-severe plaque psoriasis.
The Belgium drugmaker said that it expects global peak sales of Bimzelx to reach at least €4B.
The company added that it intends to seek FDA approval for the drug for additional indications.
Bimzelx will enter an increasingly crowded field for psoriasis drugs in the US, including AbbVie’s (ABBV) Skyrizi and Humira, Johnson & Johnson’s (JNJ) Stelara, and Novartis’ (NVS) Cosentyx.